Clinical trial
A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients…
NCT03481660 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT03481660 |
|---|---|
| Title | A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema |
| Official title | A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema |
| Acronym | KITE |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Macular Edema |
| Intervention type | Drug |
| Interventions | Brolucizumab, Aflibercept |
| Enrollment | 360 |
| Start date | Jul 27, 2018 |
| Primary completion | Jun 29, 2020 |
| Completion | Jun 8, 2021 |
| First posted | Mar 29, 2018 |
| Last update posted | Jan 7, 2025 |
| Countries | Belgium, Bulgaria, Czechia, Denmark, Estonia, France, Germany, Hungary, India, Latvia, Lebanon, Lithuania and 11 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: